Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
Lynparza (also known as olaparib) is a PARP inhibitor drug approved by the FDA to treat ovarian, fallopian tube, and primary peritoneal cancer in women who carry a BRCA mutation, and who have received three or more previous lines of chemotherapy. Lynparza has also been approved in Europe, but for a different indication: it is used there as maintenance therapy for recurrent BRCA-related ovarian cancer in women who have a good response to platinum chemotherapy.
Rubraca (also known as rucaparib) is approved to treat women with advanced ovarian cancer who have had two or more prior treatment and who have inherited mutations in BRCA or whose tumors have BRCA mutations as detected by the FoundationFocus CDxBRCA companion diagnostic.
For more information on Lynparza, Rubraca, and other PARP inhibitors in clinical trials, please see our section on targeted therapies.